2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

206 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if D-Cycloserine (DCS), taken at the same time as a child gets cognitive behavioral therapy (CBT) can help children with pediatric obsessive-compulsive disorder.

Cognitive Behavior Therapy is a talking therapy that will teach children new skills to better cope with his/her OCD. CBT usually uses "exposure-based therapy". This means that the person with OCD slowly learns to deal with things they usually avoid. This is done by moving from less stressful situations to more challenging ones.

The investigators hope to enroll about 75 children ages 7-17 years old with OCD in this study at Massachusetts General Hospital (MGH). The National Institute of Mental Health (NIMH) is paying for this study to be done.

If your child qualifies for the study, the investigators will assign him or her by chance (like a coin toss) to either the DCS group or the placebo group. You and the study doctor cannot choose your child's study group. Your child will have an equal chance (1 in 2) of being assigned to the DCS group.

Your child will be asked to take one or two capsules of the study drug (either DCS or placebo, depending which study group they were assigned to) one hour before CBT visits 4-10. The study coordinator will give your child the study drug at the location of the CBT sessions. This is to make sure that your child takes the study drug one hour before his/her scheduled therapy session. We will ask you to record any bad side effect from the study drug that your child may have before each CBT session.

It will take your child about 34 weeks to complete the study. During this time, the investigators will ask you and your child to make a minimum of 17 trips to the study center. There may be up to 23 trips when including CBT Booster sessions.

This study uses a placebo. The placebo looks exactly like the DCS, but it contains no DCS. The investigators use placebos in research studies to learn if the the results are caused by the study drug or are due to other reasons. This is a double-blind study. A double-blind study is a study where both the doctor and the study participant do not know whether the study participant is being given DCS or placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder

NCT00864123

Obsessive-compulsive Disorder

COMPLETED PHASE2

The Use of D-Cycloserine to Augment CBT for Pediatric OCD

NCT01687140

Obsessive-Compulsive Disorder

UNKNOWN PHASE2

D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)

NCT01411774

Obsessive-compulsive Disorder

COMPLETED PHASE3

D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder

NCT00257361

Obsessive Compulsive Disorder

WITHDRAWN PHASE2

D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD

NCT01172873

Obsessive Compulsive Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obsessive-Compulsive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

D-Cycloserine

Group Type ACTIVE_COMPARATOR

D-Cycloserine

Intervention Type DRUG

25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.

Sugar Pill

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Sugar pill

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D-Cycloserine

25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.

Intervention Type DRUG

Placebo

Sugar pill

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of Obsessive-Compulsive Disorder as primary or co-primary diagnosis
* Score on CY-BOCS of 16 or greater
* Full Scale IQ greater than or equal to 85
* English speaking

Exclusion Criteria

* Receiving concurrent psychotherapy or a past adequate trial of CBT for OCD
* Initiation of an antidepressant within 12 weeks before study enrollment
* Initiation of an antipsychotic within 6 weeks before study enrollment
* No new alternative medications, nutritionals, or therapeutic diets within 6 weeks of study enrollment
* Any change in established psychotropic medication within 8 weeks before study enrollment (6 weeks for antipsychotic). Alternative medications must be stable for 6 weeks prior to baseline. Any medications must remain stable during treatment.
* Current clinically significant suicidality
* Suicidal behaviors within six months
* DSM-IV conduct disorder
* DSM-IV autism
* DSM-IV bipolar
* DSM-IV schizophrenia or schizo-affective disorders
* Substance abuse within the past six months
* Hoarding symptoms (due to difficulty implementing E/RP tasks)
* Weight less than 22.5k
* Epilepsy or renal insufficiency
* Current and/or past history of alcohol abuse (DCS is contraindicated)
* Pregnant or having unprotected sex (in females)
* Presence of a significant and/or unstable medical illness that might lead to hospitalization during the study
* Known DCS allergy

Minimum Eligible Age

7 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No